Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Mifepristone Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentVentura County Health Care PlanPolicy N/A

    Cushing's - Mifepristone Care Value Policy

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage of preferred and non-preferred mifepristone tablets for adults with endogenous Cushing's syndrome and associated hyperglycemia; non-preferred products require standard prior authorization criteria or an approved exception.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyCushing's - Mifepristone Care Value Policy
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateJuly 15, 2024
    Last ReviewApr 24, 2024
    Next Review DateN/A
    Key ActionFor a non-preferred product, submit documentation showing that the patient meets the standard Cushing's mifepristone prior authorization criteria or the approved Korlym exception criteria.
    SourceLink
    POLICY UPDATE CHANGES

    A new Care Value Policy for mifepristone treatment of Cushing's syndrome was established.

    1 yearMaximum approval duration
    GenericPreferred product
    Exception requiredNon-preferred product
    AdultsCovered population
    Excluded

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Unrelated type 2 diabetes

    Coverage Criteria

    Korlym Non-Preferred Product Exception

    Coverage for Korlym as a non-preferred product requires that the patient meet BOTH A and B below.

    BOTH A and B

    • A: Patient meets the standard Cushing's - Mifepristone Prior Authorization Policy criteria.
    • BOTH i and ii

      • i: Patient has tried generic mifepristone tablets.
      • ii: Patient cannot continue to use generic mifepristone tablets due to a formulation difference in the inactive ingredient(s) (e.g., difference in dyes, fillers, or preservatives) which, per the prescriber, would result in a significant allergy or serious adverse reaction.

        Documentation required.

    Mifepristone should not be used for the treatment of type 2 diabetes mellitus unrelated to endogenous Cushing's syndrome.

    Provider Actions and Authorization Requirements

    Prior Authorization

    Product-Specific Authorization

    For the Non-Preferred Product, the patient must meet the applicable standard Cushing's mifepristone Prior Authorization Policy criteria. Requests for the Preferred Product do not have to meet the standard Prior Authorization Policy criteria.

    Note

    Approval Duration

    All approved requests are authorized for 1 year in duration.

    Documentation Required

    Supporting Documentation Required

    Submit supporting documentation when required by the criteria. Acceptable records may include chart notes, prescription claims records, prescription receipts, and/or other relevant information.

    Clinical Background

    Mifepristone is a cortisol receptor blocker used to control hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

    Key Definition

    Endogenous Cushing's syndrome
    DisorderEndogenous Cushing's syndrome is a disorder involving endogenous hypercortisolism.
    Metabolic effectThe associated hypercortisolism may cause hyperglycemia.
    Covered adult populationAdults with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance.
    Surgical statusThe policy addresses adults who have failed surgery or are not candidates for surgery.

    Non-Preferred Korlym Exception Criteria

    Non-Preferred Korlym Exception

    For the non-preferred product Korlym, coverage under the exception criteria requires ALL of the following conditions.

    All conditions required

    • The patient meets the standard Cushing's–mifepristone Prior Authorization Policy criteria.

      The standard criteria are referenced but not reproduced in this policy.

    • The patient has tried generic mifepristone tablets.
    • The patient cannot continue to use generic mifepristone tablets because of a formulation difference in inactive ingredient(s)—for example, dyes, fillers, or preservatives—that, according to the prescriber, would result in a significant allergy or serious adverse reaction.

      Documentation required.

    Required Generic Trial

    StepRequired trialRequirement before Korlym exception
    1Generic mifepristone tabletsThe patient must have tried generic mifepristone tablets before non-preferred Korlym can qualify under the exception criteria.
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyCushing's - Mifepristone Care Value Policy
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateJuly 15, 2024
    Last ReviewApr 24, 2024
    Next Review DateN/A
    Key ActionFor a non-preferred product, submit documentation showing that the patient meets the standard Cushing's mifepristone prior authorization criteria or the approved Korlym exception criteria.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and Authorization RequirementsClinical BackgroundKey DefinitionNon-Preferred Korlym Exception CriteriaRequired Generic Trial
    Documentation Required

    Formulation Exception Documentation

    For a Korlym exception, document why the patient cannot continue generic mifepristone tablets. The prescriber must identify a formulation difference in inactive ingredients—such as dyes, fillers, or preservatives—that would result in a significant allergy or serious adverse reaction.

    • The patient must have tried generic mifepristone tablets.
    • Documentation is required for the formulation-related exception.
    Denial Risk

    Unrelated Type 2 Diabetes

    Mifepristone should not be used to treat type 2 diabetes mellitus unrelated to endogenous Cushing's syndrome.

    Denial Risk

    Non-Preferred Product Denial Risk

    A Non-Preferred Product request may be denied unless the patient meets the standard Cushing's mifepristone Prior Authorization Policy criteria or an approved exception. For the Korlym exception, the patient must meet both the standard criteria and the formulation-related exception requirements.

    • Korlym exception: standard criteria must be met.
    • Korlym exception: the patient must have tried generic mifepristone tablets and be unable to continue them because of a qualifying formulation difference.